Organogenesis (NASDAQ:ORGO) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Organogenesis (NASDAQ:ORGO) posted its quarterly earnings results on Friday. The company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.02, Morningstar.com reports. The company had revenue of $64.95 million for the quarter, compared to the consensus estimate of $61.00 million. Organogenesis updated its FY 2019 guidance to EPS.

ORGO stock remained flat at $$4.27 during trading on Friday. 55,121 shares of the company traded hands, compared to its average volume of 36,073. The business has a 50-day simple moving average of $6.39. The company has a current ratio of 1.07, a quick ratio of 0.87 and a debt-to-equity ratio of 1.05. Organogenesis has a 12 month low of $3.80 and a 12 month high of $310.90.

An institutional investor recently raised its position in Organogenesis stock. Charles Schwab Investment Management Inc. boosted its holdings in shares of Organogenesis Holdings Inc (NASDAQ:ORGO) by 36.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 86,495 shares of the company’s stock after buying an additional 23,180 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.09% of Organogenesis worth $658,000 as of its most recent SEC filing. 0.99% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have recently weighed in on the stock. BTIG Research reaffirmed a “buy” rating and set a $12.00 price target on shares of Organogenesis in a research note on Sunday, May 12th. Oppenheimer began coverage on shares of Organogenesis in a report on Wednesday, April 17th. They set an “outperform” rating and a $11.00 price objective on the stock. Credit Suisse Group began coverage on shares of Organogenesis in a report on Thursday, May 2nd. They set an “outperform” rating and a $9.00 price objective on the stock. Zacks Investment Research lowered shares of Organogenesis from a “hold” rating to a “sell” rating in a report on Thursday, July 11th. Finally, CIBC began coverage on shares of Organogenesis in a report on Wednesday, April 17th. They set an “outperform” rating and a $11.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Organogenesis presently has an average rating of “Buy” and an average price target of $10.80.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

Read More: Understanding the two types of arbitrage

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.